A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with Investigator's Choice of Chemoimmunotherapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) without Del(17p) or TP53 Mutation

被引：8

作者：

Brown, Jennifer R. ^{[1
]}

Eichhorst, Barbara F. ^{[2
,3
,4
]}

Ghia, Paolo ^{[5
,6
]}

Kater, Arnon P. ^{[7
]}

Li, Jianyong ^{[8
]}

Khurana, Sudha ^{[9
]}

Elhamy, Mostafa ^{[10
]}

Wang, Min Hui ^{[9
]}

Seymour, John F. ^{[11
]}

机构：

[1] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[2] Dept 1 Internal Med, Cologne, Germany

[3] Ctr Integrated Oncol Aachen, Cologne, Germany

[4] Univ Cologne, German CLL Study Grp, Cologne, Germany

[5] Univ Vita Salute San Raffaele, Milan, Italy

[6] IRCCS Osped San Raffaele, Milan, Italy

[7] Univ Amsterdam, Dept Hematol, Canc Ctr Amsterdam, Lymphoma & Myeloma Ctr Amsterdam,Amsterdam UMC, Amsterdam, Netherlands

[8] Nanjing Med Univ, Dept Hematol, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China

[9] Acerta Pharma, San Francisco, CA USA

[10] Acerta Pharma, San Francisco, CA USA

[11] Peter Maccallum Canc Ctr, Melbourne, Vic, Australia

来源：

关键词：

D O I：

10.1182/blood-2019-123057

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4318

引用

页数：4